Physician profile
Daryl R Dutter
NPI 1578568366
$7,800.95
in general payments reported to CMS, 2019-2025
43 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,961 · 2020: $1,326 · 2021: $1,278 · 2022: $597 · 2023: $719 · 2024: $1,059 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,382.90 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $774.12 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $710.07 | 2019-2025 | Evenity, Repatha, Otezla |
| Glaxosmithkline, LLC. | $623.53 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $437.37 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $432.34 | 2019-2023 | Livalo, Seglentis |
| Lilly USA, LLC | $332.52 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $296.01 | 2020-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $264.90 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $248.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $208.16 | 2019-2023 | Vaxelis, Vaqta, Gardasil 9 |
| Otsuka America Pharmaceutical, INC. | $179.56 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $172.13 | 2019-2023 | Austedo Xr |
| Exact Sciences Corporation | $166.78 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $119.06 | 2020-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Dutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.